
HK InnoN's new drug for gastroesophageal reflux disease, 'Kaycap' (active ingredient: tegoprazan), has obtained product approval in Brazil. With this, Kaycap has become a new drug approved in 25 countries.
HK InnoN announced on the 17th that Kaycap recently received product approval from Brazil's National Health Surveillance Agency (ANVISA).
Kaycap is expected to be the first domestically produced potassium-competitive acid blocker (P-CAB) formulation to be launched in Brazil. Brazil is the largest pharmaceutical market in Latin America, and the local market for anti-ulcer drugs is known to be worth approximately 1.1 trillion won as of 2025. HK InnoN plans to expand Kaycap's position in the local market on the occasion of this product approval and strengthen its business competitiveness in the Latin American region.
The active pharmaceutical ingredient for Kaycap supplied to Brazil is scheduled to be produced at HK InnoN's Dae-so plant. The Dae-so plant obtained Good Manufacturing Practice (GMP) certification for the manufacturing and quality control of tegoprazan active pharmaceutical ingredients from Brazil's National Health Surveillance Agency (ANVISA) last year. HK InnoN aims to strengthen its supply base necessary for global market expansion by stably producing and supplying Kaycap's active pharmaceutical ingredients.
Previously, HK InnoN signed a technology transfer agreement with 'Eurofarma,' a Brazilian pharmaceutical company operating in 24 countries, in 2022. Kaycap is scheduled to be sold in Brazil under the local product name 'TREV' through the Eurofarma brand. It received approval for a total of three indications: treatment of erosive gastroesophageal reflux disease, treatment of non-erosive gastroesophageal reflux disease, and treatment of gastric ulcers.
Guok Dal-won, CEO of HK InnoN, stated, "Through the product approval in Brazil, we have once again proven Kaycap's competitiveness in the global market," adding, "We will do our utmost to ensure that Kaycap becomes a new treatment option for patients in Brazil through close cooperation with our local partner."
Kaycap, the 30th new drug of the Republic of Korea, was launched in March 2019. With rapid onset of action and secured safety for long-term use over six months, it has recorded cumulative off-hospital prescription sales of 1 trillion 43.3 billion won through the first half of this year, maintaining its No. 1 position in the domestic anti-ulcer drug market.
Kaycap has signed technology export or finished product export contracts in 55 overseas countries, including China, Southeast Asia, and Latin America. Among these, it has obtained product approval in 25 countries, including the Republic of Korea, and has been launched in 22 countries.